Evidence map›Paper›PMID 23617468›Full record

ReviewDrug and alcohol review2013

Pharmacotherapy of amphetamine-type stimulant dependence: an update.

Matthew Brensilver, Keith G Heinzerling, Steven Shoptaw

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Drug and alcohol review, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Randomized, Placebo-Controlled Trial of Targeting Neuroinflammation with Ibudilast to Treat Methamphetamine Use Disorder.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2020
    Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. The Effects of Naltrexone on Subjective Response to Methamphetamine in a Clinical Sample: a Double-Blind, Placebo-Controlled Laboratory Study.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2015
    Trial
  11. Trial
  12. Trial
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Matthew BrensilverDepartment of Family Medicine, David Geffen School of Medicine, University of California, Los Angeles, USA.
Keith G Heinzerling
Steven Shoptaw

Funding

UCLA Rapid, Relevant, Rigorous Implementation Science HubP30MH058107 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RAPHAEL J LANDOVITZ · 1997 to 2026
$53.5M
UCLA Medication Development Unit for Stimulant AbuseP50DA018185 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SHOPTAW, STEVEN J · 2004 to 2009
$5.8M
Rapid Screening of Methamphetamine PharmacotherapiesP50DA012755 · NIDA · FRIENDS RESEARCH INSTITUTE, INC. · PI SHOPTAW, STEVEN · 1999 to 2003
$4.8M
UCLA Training Program on Addiction Medicine in Primary CareT32DA026400 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SHOPTAW, STEVEN J · 2009 to 2013
$1.3M
Pharmacogenomics and Medication Development for Methamphetamine DependenceK23DA023558 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HEINZERLING, KEITH GREGORY · 2008 to 2012
$848k
NIDA NIH HHS K23 DA023558NIDA NIH HHS P50 DA012755NIDA NIH HHS P50 DA018185NIDA NIH HHS P50 DA-12755NIDA NIH HHS P50 DA-18185NIDA NIH HHS T32 DA026400NIMH NIH HHS P30 MH058107
6 · The paper itself

Abstract

issuesMethamphetamine- or amphetamine-type stimulants are the second most frequently used illicit drug worldwide, second only to cannabis. Behavioural treatments are efficacious, but their impact is limited underscoring the need for other treatment options, notably, pharmacotherapy. APPROACH: A review of randomised controlled trials of pharmacotherapies for methamphetamine- or amphetamine-type stimulants was performed using PubMed and Google Scholar databases. Evidence for efficacy of medications is reported. KEY

findingsClinical trials have yielded no broadly effective pharmacotherapy. Promising signals have been observed for methylphenidate, naltrexone, bupropion and mirtazapine in subgroups of patients in reducing stimulant use (e.g. patients with less severe dependence at baseline and men who have sex with men), though none has produced an unambiguous, replicable signal of efficacy. IMPLICATIONS: Problems in Phase II trials, including high dropout rates, missing data and a lack of agreement on outcomes, complicate efforts to find a broadly effective pharmacotherapy for amphetamine-type stimulant disorders. Efforts to address these problems include calls for better validation of pharmacological target exposure, receptor binding and functional modulation. As well, there is a need for agreement in using findings from preclinical and early phases of the medication development process for selecting better pharmacotherapy candidates.

conclusionAfter over 20 years of efforts worldwide to develop a broadly effective medication for dependence on methamphetamine- or amphetamine-type stimulants, no candidate has emerged. This highlights the need for new compounds, consistent and stringent research methods, better integration between preclinical and clinical stages of medication development, and improved collaboration between government, industry and researchers.

Indexed as

AmphetamineCentral Nervous System StimulantsAmphetamine-Related DisordersAnimalsBupropionHumansMethylphenidateNaltrexoneRandomized Controlled Trials as TopicAmphetamineBupropionCentral Nervous System StimulantsMethylphenidateNaltrexoneagonistamphetaminemethamphetaminepharmacogeneticspharmacotherapy

Identifiers

PMID23617468
PMCPMC4251965

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.